Introduction
Cytogenetics is the most powerful single prognostic factor for outcome in acute myeloid leukemia (AML) [1] [2] [3] and the most useful guide available for the stratification and planning post-remission treatment in this disease. The t (15;17) harbored by acute promyelocytic leukemia (APL) is considered among AML a favorable cytogenetic feature. However, the prognostic significance of additional cytogenetic abnormalities (ACA) in this disease has remained a matter of debate.
During the nineties, some studies suggested a relationship between ACA and outcome in APL. 4, 5 However, these studies were retrospective and performed in small series of patients mostly treated with chemotherapy alone. More recently, three studies undertaken in patients with APL treated with state-ofthe-art treatments (ie, simultaneous combination of ATRA with anthracycline-based chemotherapy) have reported conflicting results with regard to the impact on prognosis of ACA. While two large studies reported a lack of impact on the prognosis of ACA, 6,7 the third one showed that patients with ACA had a higher death rate during induction compared with those exhibiting t(15;17) alone. 8 Although none of these studies have demonstrated that ACA in APL have a significant impact on the risk of relapse, many physicians may be tempted to modify the planned treatment based on the presence of these abnormalities, extrapolating practices used for the management of other AML subtypes.
To clarify the role of ACA in APL patients treated with modern treatments, we report here the characteristics, outcome and prognostic value of cytogenetics in a large cohort of successfully karyotyped patients with long follow-up who were enrolled in two successive studies of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group (LPA96 and LPA99).
Design and Methods

Patients and eligibility
Between November 1996 and June 2005, a total of 739 de novo genetically confirmed APL patients were enrolled into LPA96 and LPA99 consecutive trials. Eligibility criteria and protocol design have been reported elsewhere.
9-11 Informed consent was obtained from all patients. According to the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each participating hospital.
Diagnosis
In addition to the morphologic and cytochemical criteria used by the FAB classification, as well as routine immunophenotyping, the diagnosis of APL was genetically confirmed in all cases by demonstration of the PML/RARA hybrid gene and/or the chromosomal translocation t(15;17)(q22;q21). Immunophenotypic and cytogenetic analyses were systematically performed at presentation only. For the purpose of rapid diagnosis, an immunohistochemical analysis of the PML protein distribution with the monoclonal antibody PG-M312 was performed in a fraction of patients.
Cytogenetics and FISH
Bone marrow samples for cytogenetic analysis were processed after short-term culture (24 or 48 hours) following standard procedures. The chromosomes were stained by G-banding and the karyotypes reported according to International System for Human Cytogenetic Nomenclature (ISCN, 1995) recommendations. 13 Whenever possible at least 20 metaphases were analyzed in each case. Studies were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 mitotic cells analyzed. In most of the patients with apparently normal karyotype and PML/RARA rearrangement demonstrated by reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH) studies were additionally carried out in metaphase and interphase nuclei. Two-color FISH was performed using a PML/RARA translocation probe (Abbott, Wiesbaden, Germany).
The majority of cytogenetic analyses were performed at reference laboratories. 
RT-PCR studies
Details on processing bone marrow samples for RNA extraction and RT-PCR protocols for PML/RARA amplification used by the participating laboratories have been described elsewhere. Details of the supportive therapy have been described elsewhere.
9,18
Definitions and Study Endpoints
Remission induction response was assessed according to the recently revised criteria by Cheson et al. 19 Molecular remission was defined as the disappearance on an ethidium bromide gel of the PML/RARA specific band visualized at diagnosis, using an RT-PCR assay with a sensitivity level of 10 -4
. Molecular persistence was defined as PCR positivity in two consecutive bone marrow samples collected at the end of consolidation therapy. Molecular relapse was defined as the reappearance of PCR-positivity in two consecutive bone marrow samples at any time after consolidation therapy. Risk of relapse was established at diagnosis according to a predictive model based on patient leukocyte and platelet counts at diagnosis, as reported elsewhere.
17 Low-risk patients had a WBC count less than 10×10 
Statistical analysis χ
2 and Fisher's exact tests were used to analyze differences in the distribution of variables among patient subsets. Unadjusted time-to-event analyses were performed using the Kaplan-Meier estimate, 20 and, for comparisons, log-rank tests. 21 For all estimates in which the event relapse was considered as an end point, hematologic and molecular relapse, as well as molecular persistence (PML/RARA positive by RT-PCR at the end of consolidation), were each considered as uncensored events. The follow-up of the patients was updated on January 15, 2009. Median follow-up of surviving patients is 85 months (range, 42 to 145). Multivariate analysis was performed using the Cox proportional hazards model.22 All computations were performed using 3D, 4F, 1L and 2L programs from the BMDP statistical library (BMDP Statistical Software Inc, Los Angeles, CA, USA).
Results
Incidence and characteristics of chromosomal abnormalities
Between November 1996 and June 2005, a total of 739 de novo genetically confirmed APL patients were enrolled from 82 institutions from Spain, The Netherlands, Belgium, Argentina, Uruguay, and the Czech Republic (see Appendix), in the LPA96 and LPA99 consecutive trials. A diagnostic result of cytogenetics was not available in 244 cases either because cytogenetic studies were not performed (n= 32) or failed (n = 191), while the reason was unknown in the remainder. Failures in cytogenetic analysis were due to absence of metaphases (n = 124) or either poor quality or insufficient number of metaphases (n = 67). All these patients were genetically diagnosed by FISH, RT-PCR or anti-PML staining. Among the remaining 495 patients (67%) three hundred and fifty-five patients (72%) had the t(15;17) translocation as the sole chromosomal abnormality and 140 patients (28%) had ACA; 95 of the patients had one additional abnormality (67%) and 45 had two or more abnormalities (33%) ( Table 1) . Trisomy 8 (n=51), either alone (n=37) or associated with other aberrations (n=14), was the most frequent abnormality (36%), followed by other less frequent numerical and structural aberrations listed in Table 1 .
Double color FISH studies, RT-PCR or both showed PML/RARA fusion gene in the 71 patients with available karyotype in which the t(15;17) was not detected by conventional cytogenetics. In 45 of these patients the karyotype was normal while in the remaining 26 cases the karyotype showed other cytogenetic changes but not the t(15;17) ( Table 1) . (13) 10 (14) 64 (13) Abn (7q) 6 (1) 1 (1) 
Cytogenetic abnormalities and disease characteristic
The main clinical and biological characteristics of patients without an available karyotype and those with either t(15;17) alone or t(15;17) with ACA are shown in Table 2 . Patients with ACA had significantly lower platelet counts (p=0.02) and therefore were classified less frequently as low-risk (p=0.02) compared with those without ACA. A similar association with platelet counts and relapse-risk score was also observed according to the number of ACA. Patients with 2 or more ACA had significantly lower platelet counts (p=0.02) and were classified less frequently as low-risk (p=0.02) compared with those with 1 ACA. In addition, patients with ACA displayed coagulopathy more frequently (p=0.03) and, although not statistically significant, tended to be younger (p=0.05) and have more frequently the BCR3 PML/RARA isoform than patients with t(15;17) alone (p=0.08). Patients with trisomy 8 had significantly more fever at diagnosis (p=0.01), coagulopathy (p=0.02), fibrinogen levels <170 mg/dL (p=0.02), male gender (p=0.05), uric acid serum levels>7 mg/dL (p=0.02), bone marrow blasts >70% (p=0.03), and tended to have lower platelet counts (p=0.07), compared with those without trisomy 8. Clinicopathologic characteristics of patients with trisomy 8 alone did not differ from those of patients with trisomy 8 plus other abnormalities.
Influence of additional cytogenetic abnormalities on outcome in APL Three hundred and twenty-five of the 355 patients (91%) with the t(15;17) alone and 126 of the 140 (90%) with ACA achieved CR. This difference was not statistically significant (Table 3) . CR rate did not differ in patients with unavailable or inadequate cytogenetics (89%, p=0.26).
Concerning the subsequent clinical outcome of patients who achieved CR, a total of 53 relapses were recorded (34 clinical and 19 molecular relapses, including 5 with molecular disease persistence after consolidation therapy). The overall 5-year relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS) rates were 88%, 85%, and 83%, respectively. RFS, DFS and OS in patients with unavailable or inadequate cytogenetics were 85%, 80%, and 76% (p=0.28, p=0.12, and p=0.08, respectively).
Univariate analysis of RFS is shown in Table 4 . In patients with available karyotype, when both protocols LPA96 and LPA99 are considered together, several variables were statistically significant, such as gender, relapse-risk score, morphological subtype, and PML/RARA isoform, but the presence of ACA did not achieve statistical significance (p=0.10). When analyzed separately, trisomy 8 was associated with a statistically lower RFS compared with the absence of trisomy 8 (78% vs. 89%,p=0.3). The RFS was lower according to the number of chromosomal abnormalities detected by conventional karyotype, but it was not statistically significant (5-year RFS of 93% in patients with normal karyotype; 89% in patients with t(15;17) alone; 86% with 1 ACA; 83% with 2 ACA; and 78% with ≥3 ACA; p=0.34) ( Table 1) . Multivariate analysis identified relapse-risk score and male gender as the only independent adverse factors for RFS (p<0.0001 andp=0.03, respectively).
Due to the better outcome of the LPA99 trial compared with the LPA96 reported in previous analyses of this series when patients with and without available karyotype were included, 10, 11 we have performed an analysis separately by protocol ( Table 4 ). The univariate analysis showed that the presence of ACA at diagnosis was significantly associated with lower RFS in the LPA99 trial (82% vs. 92%, p=0.01) ( Figure 1A ), but not in the LPA96 trial (89% vs. 81%, P =.33). In the LPA99 trial, univariate analysis also showed a lower RFS for patients with trisomy 8 (77% vs. 91%, p=0.02) ( Figure  1B) . Multivariate analysis showed that in addition to relapse-risk score and male gender, BCR3 isoform was an independent adverse factor for RFS in the LPA99 trial, but not the presence of ACA.
Discussion
This study shows that roughly one third of patients with APL display ACA over and above the t(15;17). Among these secondary chromosome aberrations, trisomy 8 is by far the most frequent abnormality, i.e., with a prevalence of around one third of these cases. In the context of a state-of-the-art treatment based on the combination of ATRA and anthracycline-based chemotherapy, the presence of ACA, mainly 2 or more, or of trisomy 8 were associated with lower platelet counts and a higher relapse-risk score that resulted in lower RFS. However, multivariate analysis showed that the presence of neither ACA nor trisomy 8 is an independent adverse factor of relapse.
With regard to the incidence of ACA in APL, overall, it has been consistently reported within a range between 26% and 39%,1,4-8,23 trisomy 8 being the most frequent abnormality (33% to 53% of secondary changes). The incidence of ACA and the proportion of trisomy 8 among these abnormalities reported in the present study, 28% and 36%, respectively, are both within the ranges reported in the literature. It should be noted, however, that abn(7q), the most common abnormality after trisomy 8, usually ranging from 5% to 8%4-6,24 (in our study 5% of additional aberrations), but a recent study by the German AML Study Group (AMLSG) found a higher proportion (27% of aberrations).
8 However, this study was based on a small series of 7 patients displaying this abnormality among only 26 patients with additional changes. The relative high frequency of some additional chromosome abnormalities, particularly the trisomy 8, may suggest the appropriateness of performing a systematic FISH analysis including a centromeric probe of chromosome 8 in the diagnostic work up, and perhaps be extended to the detection of the del(7q). As it has been previously reported,14 we found that patients with t(15;17) not detected by conventional karyotype had the same pattern of ACA as patients with conventional t(15;17), with chromosome 8 abnormalities being most common. This finding would suggest that the ACA are important cooperating lesions in leukemogenesis of APL. Regarding the clinicopathologic characteristics, as far as we know, the association of ACA with low platelet counts, intermediate-and high-risk group, and presence of coagulopathy found in the present study has not been previously reported. At the molecular level, a previous report described a relationship between the breakpoint at BCR3 region and the presence of ACA. 4 Our results do not demonstrate a significant relation between the BCR3 isofom and the presence of ACA, but it tended to be associated (p=0.08). Another interesting relationship has been recently suggested between additional chromosomal abnormalities and the mutational status of FLT3 gene. 24, 25 The MRC study 24 revealed an inverse relationship between frequency of FLT3/ITD and presence of ACA accompanying t(15;17) analyzed by conventional cytogenetics. This finding has also been reported by Akagi et al. 25 who analyzed ACA with high-density single-nucleotide polymorphism microarray to detect copy-number-neutral loss of heterozygosity. Interestingly, FLT3/ITD mutations occurred only in the group with no genomic alterations. Although this mutation occurred in our series in a lower proportion among patients with trisomy 8 (11.5%) compared with those with other ACA (24.3%) or without ACA (22.8%), this difference was not statistically significant.
Although the AMLSG study8 reported that patients dying during induction therapy had significantly higher initial WBC counts and a higher likelihood of exhibiting trisomy 8 or abn(7q) as additional chromosomal aberrations, no other study has described such association between cytogenetics and induction outcome. Indeed, we also found that patients with ACA had a similar induction death rate compared with those with only the t(15;17).The association observed in the present study between ACA and coagulopathy, that is potentially implicated in an increased risk of induction death, 18 could explain in part the results of the German study.
As far as we know, only two contradictory reports coming from small series of the pre-ATRA era have previously showed some association between ACA and relapse. 4, 5 The study by Hiorns et al. 5 in 54 patients (44 treated without ATRA) showed that relapse-free survival was significantly correlated with karyotype. In this study, patients without ACA and low WBC count had a significant RFS advantage over other combinations of these factors. In contrast, the study by Slack et al,4 carried out in 80 patients treated with chemotherapy alone, found that the presence of a secondary chromosome abnormality was associated with a longer complete remission duration. Based on a large series of patients treated with ATRA plus anthracycline-based chemotherapy with prolonged follow up, our study does not confirm a significant RFS disadvantage in APL patients with ACA. It should be noted that the adverse prognostic impact of ACA on relapse observed in the LPA99 trial, which was not independent of relapse-risk score, male gender, and BCR3 isoform, was not observed in the LPA96 trial. Apart from differences in sample size that can explain a different impact of ACA in the LPA96 and LPA99 trials, it is well known that the efficacy of therapy can have a critical influence on the prognostic significance of other variables. In this regard, previous reports have demonstrated a lower RFS in the LPA99 trial 10,11 that may contribute to alter the prognostic value of many variables, including ACA. We can also speculate that the adverse impact on RFS showed in univariate analysis for ACA in the LPA99 trial, can be masked in multivariate analysis due to its association with intermediate-and high-risk groups and BCR3 isoform. It would be conceivable that ACA in general, or some specific abnormality in particular (eg, trisomy 8), might have a role in generating the factors leading to poorer risk score. Further studies to confirm and elucidate the relative importance of these variables are warranted.
In conclusion, this study confirms that one third of patients with de novo APL display ACA at diagnosis, trisomy 8 being the more frequent abnormality. Patients with ACA had significantly more coagulopathy, and were less frequently classified as low-risk group of relapse. Although ACA and trisomy 8 were significantly associated with lower RFS, they were not identified as independent risk factors of relapse, probably due to their association with relapse-risk score. Until confirmation of this hypothesis, additional therapeutic strategies are not required in APL patients with ACA, at least in the context of ATRA plus anthracycline monochemotherapy-based regimens. 
